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including colitis, anorexia, stomatitis plus hand-foot syn-
drome. One partial response, 5 disease stabilizations, and 3 
disease progressions were reported.
Conclusions Combination of pegylated liposomal doxo-
rubicin and lapatinib is feasible and potentially active in 
pretreated HER2-positive advanced breast cancer patients.
Trial registration NCT02131506 (ClinicalTrials.gov 
identifier).
Keywords Breast cancer · HER2 · Targeted therapy · 
Lapatinib · Pegylated liposomal doxorubicin · Phase Ib
Introduction
Breast cancer (BC), the most frequent cancer worldwide 
among women, and one of the main leading causes of can-
cer death [1], consists of different subtypes according to 
biology, prognosis, and treatment response [2].
Before the advent of anti-human epidermal growth fac-
tor receptor 2 (HER2) therapies, survival of metastatic 
HER2-positive BC patients was quite poor [3]. The advent 
of targeted therapies has led to impressive improvements 
in survival [4]. Nonetheless, long-term outcome data show 
that only about 12% of patients maintains disease remission 
after 5 years of first-line trastuzumab-based therapy [5], 
and almost all patients eventually undergo disease progres-
sion and require additional therapies. Although evidence of 
benefit from HER2-targeted therapies beyond second-line 
treatment of metastatic BC is not definitive [6], its use is 
common in clinical practice and is recommended by treat-
ment guidelines [7].
Anthracyclines are among the most active drugs in 
BC [8], and have been hypothesized [9] to be particularly 
effective in HER2-positive tumors [10]. Given the cardiac 
Abstract 
Purpose Combination of anthracyclines with trastuzumab 
is hampered by cardiotoxicity. Pegylated liposomal doxo-
rubicin and lapatinib could represent a safer alternative to 
combination therapy.
Methods In this phase Ib study with 3 + 3 dose escala-
tion design, patients with HER2-positive advanced breast 
cancer received pegylated liposomal doxorubicin 30 mg/m2 
intravenously on day 1 plus lapatinib 1250 (level 1) or 1500 
(level 2) mg/day orally on days 1–21 of each 21-day cycle. 
The aims were to establish the maximum tolerated dose at 
first cycle, and the activity and safety of multiple cycles.
Results Nine patients out of 11 enrolled were evalu-
able: 3 at level 1 and 6 at level 2. No dose-limiting tox-
icities occurred at dose level 1, while 1 (grade 3 diarrhea) 
occurred at dose level 2, leading to the expansion of this 
cohort to 6 patients, with no further dose-limiting tox-
icities. Main grade 1–2 toxicities at first cycle were leu-
copenia, diarrhea, elevated transaminases, mucositis. 
Three patients had grade 3 toxicities at subsequent cycles, 
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toxicity caused by both drugs [11, 12], the administration 
of conventional anthracyclines concomitantly with trastu-
zumab results in unacceptable rates of heart failure, espe-
cially in the metastatic setting [4], when long-term thera-
pies are administered. As a consequence, antracyclines 
remain underused for HER2-positive metastatic BC in 
clinical practice, with only about 25% of eligible patients 
treated [13].
Liposomal formulations of doxorubicin appear to main-
tain similar efficacy with a reduced risk of cardiotoxicity 
compared to conventional doxorubicin [14]. Pegylated lipo-
somal doxorubicin (PLD) has been approved by the Euro-
pean Medicines Agency for use as monotherapy in patients 
with metastatic BC in event of increased cardiac risk (PLD 
summary of product characteristics).
Lapatinib (L), a small molecule, reversible dual tyrosine 
kinase inhibitor selectively targeting HER2 and epidermal 
growth factor receptor (EGFR), is indicated for the treat-
ment of adult patients with HER2-positive advanced or 
metastatic BC in combination with either capecitabine (fol-
lowing progression after therapy including anthracyclines, 
taxanes, and trastuzumab in the metastatic setting) or tras-
tuzumab (in hormone receptor-negative disease progress-
ing on prior trastuzumab) or with an aromatase inhibitor 
(in postmenopausal women with hormone receptor-pos-
itive disease, not currently intended for chemotherapy) (L 
summary of product characteristics). L causes low car-
diotoxicity, usually consisting in asymptomatic, reversible 
decreases in left ventricular ejection fraction (LVEF), inde-
pendently from pretreatment with anthracyclines or trastu-
zumab [15].
Preclinical work shows an additive cytotoxic effect of 
the combination of L and PLD in HER2-positive BC cell 
lines, and a potential synergy in other EGFR-positive/
HER2-negative cell lines [16].
We designed a phase Ib clinical trial with the aim to 
define the maximum tolerated dose (MTD) and the recom-
mended phase-2 dose (RP2D) of this drug combination.
Materials and methods
Study design
This was an open label, phase Ib study, with standard 3 + 3 
dose escalation design.
The primary objectives were to define MTD, based on 
the dose-limiting toxicities (DLTs) observed during the first 
cycle of treatment, and RP2D.
Secondary objectives were to explore the antitumor 
activity, in terms of objective response rate and clinical 
benefit, and to assess the safety profile of multiple cycles of 
therapy, especially cardiac.
Four dose levels were planned: the starting dose level 
1, with PLD 30 mg/m2 and L 1250 mg/day; dose level 2, 
with PLD 30  mg/m2 and L 1500  mg/day; dose level 3, 
with PLD 40 mg/m2 and L 1500 mg/day; and dose level-
1, with PLD 30 mg/m2 and L 1000 mg/day.
Cohorts of 3–6 patients were required for treatment 
at successive dose levels, starting at level 1. If none of 
the initial 3 patients for each dose level developed a 
first-course DLT, the following cohort could start 1 
dose level higher. If 1 of the initial 3 patients developed 
a first-course DLT, a maximum of 3 additional patients 
were to enter at the same level. MTD was defined as 
the dose level at which ≥33.3% of the patients experi-
enced first-course DLT. If the cohort below MTD, i.e., 
RP2D, included 3 patients, the cohort was expanded to 6 
patients.
DLT was defined as any of the following first-cycle 
events: grade (G) 4 neutropenia (absolute neutrophil 
count [ANC] < 500 cells/mm3) for ≥5 days, or febrile 
neutropenia (fever ≥ 38.5 °C with ANC < 1000 cells/
mm3); G4 thrombocytopenia (platelet count <25,000 
cells/mm3), or G3 thrombocytopenia associated with a 
bleeding episode requiring platelet transfusion; G ≥ 3 
non-hematological toxicity; failure to readminister treat-
ment within 14 days of the planned drug administration 
due to delayed recovery of treatment-related toxicity to 
G ≤ 1 or baseline.
Toxicity was graded according to the Common Termi-
nology Criteria for Adverse Events (CTCAE) version 3.0.
Treatment was discontinued in case of disease progres-
sion, unacceptable toxicity, appearance of intercurrent 
illnesses or clinical conditions which jeopardized con-
tinuation of therapy, or patient decision to withdraw from 
the study. If interruption of PLD was clinically indicated, 
patients could continue to receive L monotherapy.
Study treatment
Each 21-day cycle included L administered orally once 
daily (1  h before or after breakfast) on days 1–21, and 
PLD administered intravenously (i.v.) in a 60 minutes’ 
infusion on day 1 (the first dose was started more slowly 
to minimize the risk of infusion reactions). Thirty min-
utes before PLD administration, patients received dexa-
methasone 8  mg i.v. and ondansetron 8  mg i.v. Anti-
emetic medications were prescribed for the following 
days as needed. Patients were required to comply with 
the prescribing information for L, including avoidance of 
inducers and strong inhibitors of CYP3A4; medications 
for increasing gastric pH may have been taken within 1 h 
of administration of L, if strictly needed.
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Dose adjustments
Treatment was temporarily withheld in the event of G4 
hematological or G ≥ 3 non-hematological toxicity or G ≥ 2 
left ventricular systolic dysfunction (LVSD). Delay of sub-
sequent cycles occurred in case of G ≥ 2 hematological 
on non-hematological toxicity on day 1. Dose reductions 
were adjusted according to the worst toxicity occurred in 
the previous cycle, with a reduction of 1 L dose level and 
25% of PLD dose in the event of febrile neutropenia, G4 
thrombocytopenia or bleeding associated with thrombo-
cytopenia, or G ≥ 3 non-hematological toxicity. Definitive 
treatment interruptions were planned in case of G3 or G4 
LVSD, G4 rash manifested as toxic epidermal necrolysis/
Stevens-Johnson’s Syndrome, liver toxicity fulfilling Hy’s 
law (ALT > 3 × ULN and total bilirubin > 2.0 × ULN).
Safety and tumor assessments
Baseline evaluation included medical history (with con-
comitant medications) and physical examination, vital 
parameters and ECOG performance status (PS), cardiologic 
examination including ECG and echocardiography, labora-
tory assessments (hematology and blood chemistry, includ-
ing high-sensitivity troponin T [TnT-hs] and N-terminal 
pro b-type Natriuretic Peptide [NT-proBNP]), and tumor 
assessment with CT scan of the thorax and abdomen. Brain 
CT scan and bone scintigraphy, as well as other imaging 
studies, were performed if clinically indicated.
Complete blood count and blood chemistry were 
repeated weekly. Toxicity, physical examination, vital 
parameters, and PS were assessed before each cycle. Car-
diac monitoring included biomarker measurement before 
(TnT-hs + NT-proBNP) and 24  h after (TnT-hs) PLD 
administration, as a correlative research evaluation, and 
ECG + cardiologic exam and echocardiogram (with meas-
urement of LVEF) every 2 cycles of therapy.
Imaging studies for tumor evaluation were performed 
every third cycle and whenever clinically indicated.
Patient population
The main inclusion criteria were: histological or cytologi-
cal diagnosis of BC; locally advanced (stage IIIB–IIIC) 
inoperable or metastatic (stage IV) disease; HER2 overex-
pression, defined as +3 staining in immunohistochemistry, 
or HER2 amplification at fluorescence in situ hybridization 
(FISH); age ≥18 years; ECOG performance status ≤2; life 
expectancy ≥12 weeks; disease progression following prior 
therapy with taxane- and trastuzumab-containing regimens 
(if not contraindicated); previous cumulative doxorubicin 
dose ≤240  mg/m2; LVEF within the institutional range of 
normal; adequate bone marrow, liver, and renal functions; 
and ability to understand and willingness to sign a written 
informed consent document.
Exclusion criteria included: prior exposure to PLD or 
L, history of allergic reactions to compounds of similar 
chemical composition, prior treatment with anthracyclines 
within 1  year of study entry or prior disease progression 
while on anthracycline therapy, a pregnant or lactating sta-
tus, non-compliance with adequate contraceptive measures 
for patients with reproductive potential, prior or concurrent 
history of other neoplasms, symptomatic brain metastases, 
and uncontrolled intercurrent illnesses.
All patients signed a written informed consent. The 
study was approved by the Scientific and the Ethics Com-
mittees of our Institute, and performed in accordance with 
the Declaration of Helsinki and the Good Clinical Practice 
guidelines. ClinicalTrials.gov identifier: NCT02131506.
Statistical analysis
Descriptive statistics are reported for patients’ characteris-
tics and response analysis. The Kaplan–Meier method was 
used to analyze the time-to-event endpoints. After visually 
checking homoscedasticity and normality of residual plots, 
a linear mixed effects model, with random intercepts and 
slopes, was fitted to evaluate changes of LVEF over time, 
with time as fixed effect and subjects as random effect. 
Analyses were done using R (R Core Team 2015) and the R 
lme4 package.
Results
Between February 2010 and June 2015, 11 patients were 
enrolled into the study, 9 of whom were evaluable. A 
45-year-old woman with metastatic HER2-positive lobular 
carcinoma, pretreated with trastuzumab plus pertuzumab 
plus docetaxel for 2 cycles (in the Cleopatra trial), switched 
to vinorelbine plus trastuzumab because of an allergic reac-
tion to docetaxel, was considered non-evaluable because 
of a grade 3 allergic reaction occurring immediately after 
the beginning of the first PLD infusion. A 65-year-old 
woman with metastatic HER2-positive lobular carcinoma, 
pretreated with 2 lines of trastuzumab-based therapy, with-
drew her consent before starting therapy.
Characteristics of the 9 evaluable patients are reported 
in Table  1. Median age was 65 years (range 43–77). All 
patients had HER2-positive tumors of ductal histology, 
7 of whom were hormone receptor positive, and 5 had 
Ki67 ≥20%. Only 3 patients were pretreated with adjuvant 
chemotherapy, including anthracyclines in 2 cases, and 
2 had adjuvant trastuzumab. All but 1 were pretreated for 
metastatic disease, including ≥2 lines of trastuzumab-based 
treatment in most cases. The only patient not pretreated for 
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metastatic disease was a 75-year-old lady who had disease 
relapse right at the end of adjuvant trastuzumab (prior to 
T-DM1 registration); she received doxorubicin + cyclo-
phosphamide for 4 cycles and 12 weekly administrations of 
paclitaxel in the adjuvant setting; at the time of relapse, she 
refused treatment-induced alopecia, and was not candidate 
to lapatinib + capecitabine according to the Italian lapatinib 
indication; therefore, after careful discussion, treatment 
within the trial appeared a good option and was acceptable 
for the patient. All had good performance status, although 
most had ≥2 metastatic sites and visceral involvement.
Of the nine patients, three were enrolled at dose level 1. 
As none of these patients developed DLT at first cycle, the 
second cohort started at dose level 2. Among the first three 
patients of the latter cohort, 1 presented a DLT (G3 diar-
rhea at first cycle), leading to the expansion of the cohort to 
6 patients, with no further occurrence of DLT.
The median number of treatment cycles were 7 for PLD 
(range 3–13) and 6 for L (range 1–26). The median dose 
intensity of PLD was 9.4  mg/m2/week (range 8.3–10.0). 
During the whole course of therapy, the median dose inten-
sity of L was 1195 mg/day (range 996–1500) (dose level 1: 
median 1195, range 996–1225; level 2: median 1220, range 
1048–1500).
First cycle toxicities are reported in Table  2. One case 
of neutropenia and 1 of elevated transaminases represented 
the only G2 events at first dose level, with G1 leucopenia, 
nausea, anorexia, and diarrhea as additional side effects. 
Diarrhea was the predominant adverse event at dose level 
2, with 1 case of G3 (DLT) and 2 cases of G1 and G2 each. 
The only other G2 event was a case of hyperbilirubinemia, 
which was not associated with elevation of transaminases, 
and therefore not considered a concern for serious liver 
injury. Other G1 events included leucopenia, neutropenia, 
anemia, fatigue, mucositis, epigastric pain.
Toxicities recorded along the whole treatment period 
are reported in Table 3. There were no G4 adverse events, 
and there was only 1 G3 event represented by colitis at 
dose level 1, and 4 G3 events at dose level 2, represented 
by diarrhea (already reported above as DLT at first cycle), 
hand-foot syndrome, mucositis, and anorexia, respectively. 
The most common G1–2 non-hematological adverse events 
were hand-foot syndrome, rash, fatigue, mucositis, epigas-
tric pain, hyperbilirubinemia, transaminases elevation, and 
diarrhea. Hematological adverse events included G1–2 
neutropenia in 6 patients, leucopenia in 5 patients, and ane-
mia in 2 patients.
Regular comprehensive cardiologic evaluations were 
performed as described above. No cases of LVSD were 
reported, defined as a LVEF reduction to ≤50 percentage 
points or a LVEF reduction of >20 percentage points of 
the baseline value (Fig. 1a), and actually no cases of LVEF 
reduction ≥10% points of the baseline value occurred. 
Median baseline LVEF was 67% (range 59–77%, mean 
68%) and median LVEF at nadir was 67% (range 59–73%, 
mean 66%). The analysis of LVEF measures did not show 
significant changes over time (p = 0.26, mixed effects 
model). Two patients prudently stopped PLD after 13 and 
Table 1  Patient and tumor characteristics (for the 9 evaluable 
patients)
a In two patients, an endocrine agent was substituted for paclitaxel as 
maintenance therapy, in combination with trastuzumab, after about 6 



















HER2 status positive 9 (100)
Previous (neo)adjuvant chemotherapy
 With antracyclines 2 (22)
 Without antracyclines 1 (11)
Previous (neo)adjuvant trastuzumab 2 (22)





 Trastuzumab plus  taxanea 7 (78)
 Trastuzumab plus endocrine agent 2 (22)
 Trastuzumab plus vinorelbine/capecitabine 4 (44)
 T-DM1 2 (22)
 Neratinib plus capecitabine 1 (11)
 Cyclophosphamide plus docetaxel 1 (11)




 Soft tissues 2 (22)
 Bone 6 (67)
 Viscera 6 (67)
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10 cycles, respectively (corresponding to cumulative doses 
of 390 and 300 mg/m2, respectively), but had no significant 
changes in LVEF. Two patients had temporary increases 
in TnT-hs levels above the rule-out value for myocar-
dial damage of 10  ng/L, but well below the rule-in value 
for myocardial damage of 50 ng/L, with values of 20 and 
21 ng/L, respectively, which did not increase over time and 
were considered not clinically significant (Fig.  1b). All 8 
patients evaluable for NT-proBNP had levels within normal 
limits throughout the study period (Fig. 1c).
Table 2  First cycle toxicity 
(N = 9 patients)
G grade of toxicity
a n = number of patients experiencing a given toxicity
Dose level 1 Dose level 2 Overall
na na na
G1 G2 G3 G4 G1 G2 G3 G4 G1 G2 G3 G4
Leucopenia 1 0 0 0 3 0 0 0 4 0 0 0
Neutropenia 1 1 0 0 1 0 0 0 2 1 0 0
Anemia 0 0 0 0 1 0 0 0 1 0 0 0
Fatigue 0 0 0 0 1 0 0 0 1 0 0 0
Nausea 1 0 0 0 0 0 0 0 1 0 0 0
Anorexia 1 0 0 0 0 0 0 0 1 0 0 0
Mucositis 0 0 0 0 2 0 0 0 2 0 0 0
Hyperbilirubinemia 0 0 0 0 0 1 0 0 0 1 0 0
Epigastric pain 0 0 0 0 1 0 0 0 1 0 0 0
Elevated Transaminases 1 1 0 0 1 0 0 0 2 1 0 0
Diarrhea 1 0 0 0 2 2 1 0 3 2 1 0
Table 3  Overall treatment-
related toxicities (N = 9 patients)
G grade of toxicity
a n = number of patients experiencing a given toxicity (each patient was registered under the maximum 
grade experienced for each kind of toxicity experienced)
Dose level 1 Dose level 2 Overall
na na na
G1 G2 G3 G4 G1 G2 G3 G4 G1 G2 G3 G4
Leucopenia 1 1 0 0 1 2 0 0 2 3 0 0
Neutropenia 1 2 0 0 2 1 0 0 3 3 0 0
Anemia 0 0 0 0 1 1 0 0 1 1 0 0
Hypercholesterolemia 0 0 0 0 1 0 0 0 1 0 0 0
Hand-foot syndrome 0 1 0 0 1 2 1 0 1 3 1 0
Rash 0 1 0 0 1 0 0 0 1 1 0 0
Pneumonia 0 0 0 0 1 0 0 0 1 0 0 0
Fatigue 0 0 0 0 3 2 0 0 3 2 0 0
Nausea 0 0 0 0 1 0 0 0 1 0 0 0
Vomiting 0 1 0 0 0 0 0 0 0 1 0 0
Anorexia 0 0 0 0 0 0 1 0 0 0 1 0
Mucositis 0 2 0 0 3 1 1 0 3 3 1 0
Hyperbilirubinemia 0 0 0 0 1 1 0 0 1 1 0 0
Epigastric pain 1 0 0 0 1 0 0 0 2 0 0 0
Elevated transaminases 2 1 0 0 2 1 0 0 4 2 0 0
Diarrhea 1 0 0 0 2 2 1 0 3 2 1 0
Hypercreatininemia 1 0 0 0 0 0 0 0 1 0 0 0
Hypokalemia 0 0 0 0 1 0 0 0 1 0 0 0
Colitis 0 0 1 0 0 0 0 0 0 0 1 0
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Temporary interruptions of L were necessary in eight 
patients (median 6 days, range 2–24), mainly for diarrhea, 
mucositis, or skin toxicity; delayed administrations of PLD 
were necessary in five patients (median 1 week, range 1–4 
weeks, with subsequent dose reductions in 2 cases), mainly 
for diarrhea, mucositis, skin toxicity, or leucopenia.
Definitive interruption of either or both study drugs 
for reasons other than disease progression occurred in 
5 patients: one prudently stopped PLD after a cumula-
tive dose of 390  mg/m2; one stopped PLD after 9 cycles 
out of a personal choice; one, pretreated with doxorubicin 
240 mg/m2, prudently stopped PLD after a cumulative dose 
of 300 mg/m2, and continued with L plus anastrozole out-
side the study; one stopped L after the first cycle, because 
of G3 diarrhea (DLT) recurring also after dose reduction 
to 1000  mg/day, and stopped PLD for medical decision 
(later switched to maintenance endocrine treatment) after 
7 cycles; one stopped L after 2 cycles due to toxicity (G3 
anorexia).
Because of the long-term intent of the treatment, and the 
occurrence of G3 adverse events beyond the first cycle, we 
decided to discontinue patient enrollment into dose level 3; 
dose level 2 was considered as the RP2D.
Median follow-up was 22 months. Best responses 
were: one partial response, 1 stable disease and 1 disease 
progression at dose level 1; four stable diseases and two 
disease progressions at dose level 2. Overall, six patients 
had clinical benefit (objective response or disease stabili-
zation ≥4 months). With a median follow-up of 96 weeks, 
median time to progression was 23 weeks.
Discussion
Our study shows that combination of PLD and L is feasible 
without raising new specific toxicity concerns. In particu-
lar, no cardiac adverse events were reported, and an accu-
rate assessment of the circulating cardiac biomarkers TnT-
hs and NT-proBNP, along with ultrasonographic studies 
of the cardiac function, detected no signs of early cardiac 
damage. No G4 toxicities occurred; the most important G3 
events were expected from the use of the two agents, i.e., 
hand-foot syndrome and mucositis for PLD and diarrhea 
for L. Liver toxicity was present but ≤G2, and no cases 
of severe drug-induced liver injury were reported. Fur-
thermore, hematological toxicity was never >G2, ensuring 
treatment tolerability also in heavily pretreated patients.
The treatment showed hints of activity, with 1 objec-
tive response and five disease stabilizations among nine 
a b
c
Fig. 1  Temporal trends of cardiac parameters and biomarkers: a left 
ventricular ejection fraction (LVEF, normal value ≥55%); b high-sen-
sitivity troponin T (TnT-hs, normal value <10 ng/L; rule-in value for 
myocardial damage >50  ng/L); c N-terminal pro b-type Natriuretic 
Peptide (NT-proBNP, normal value <450 pg/ml)
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evaluable patients, most of whom were pretreated with ≥2 
lines of anti-HER2 therapy for advanced disease.
The pegylated liposomal formulation of doxorubicin 
favors drug delivery to the tumor, protection from normal 
organ toxicity, and prolonged half-life [17]. These features 
contribute to a better therapeutic index than with conven-
tional doxorubicin, as documented by a randomized phase-
III trial showing non inferior progression-free survival 
(PFS) with PLD, with significantly reduced risk of car-
diotoxicity [18]. A better cardiac tolerance was confirmed 
with endomyocardial biopsies in patients treated with high 
cumulative doses of PLD [19]. Moreover, PLD was proven 
to be feasible and active in patients pretreated with neo-/
adjuvant anthracyclines [20, 21].
L, a reversible dual inhibitor of EGFR and HER2 tyros-
ine kinases, effectively inhibits the main downstream path-
ways of these receptors, inhibiting cell proliferation and 
survival, and inducing the expression of pro-apoptotic mol-
ecules [22]. In phase-III randomized trials, L was shown to 
improve PFS when added to capecitabine or to letrozole in 
patients with HER2-positive advanced BC [23, 24].
The rate of cardiac events with L, either in monother-
apy or in combination with drugs other than anthracy-
clines, was reported to be 1.6% in a pooled analysis of 3689 
patients [15], with mean time to onset of 13 weeks, partial 
or full recovery in 88% of the cases, and rate of sympto-
matic congestive heart failure of 0.2%. A rate of 2.2% of 
cardiac events was observed with L in patients pretreated 
with conventional anthracyclines [15]. Data on L are con-
sistent with type II cardiotoxicity, characterized by a usu-
ally reversible myocyte dysfunction, without necrosis. On 
the contrary, anthracyclines lead to myocyte damage and 
necrosis, mainly as a result of topoisomerase-2β inhibition 
[25]. The reduced myocyte damage occurring with PLD, 
compared with conventional anthracyclines, and the lim-
ited functional damage associated with L, might allow their 
combined administration. A combination of trastuzumab 
with non-pegylated liposomal doxorubicin and paclitaxel 
has been shown to be tolerable, with a rate of grade 3–4 
heart failure of 3% and treatment discontinuation due to 
LVEF decrease in 6% of the patients [26]. The PLD + L 
combination could be expected to be less cardiotoxic than 
the above triplet, although its cardiac safety must be evalu-
ated in adequately powered trials.
Both PLD and L are suitable for long-term treatments, 
which is particularly crucial in the metastatic setting, and 
is confirmed by the limited toxicity registered in our study. 
Nonetheless, safety of long-term administration needs be 
confirmed in larger studies.
Concerning efficacy and potential synergy or additiv-
ity, preclinical studies have shown that L blocks efflux 
pumps such as the breast cancer resistance protein (BCRP/
ABCG2), leading to increased intracellular accumulation of 
chemotherapeutic agents when administered concomitantly 
[16, 27]. Concomitant treatment of L and PLD showed 
additive effects in HER2-positive BC cell lines, and a 
potential synergy in other EGFR-positive, HER2-negative 
cell lines. Despite some conflicting data [28], this HER2-
independent mechanism of action could prove useful espe-
cially in heterogeneous tumors, where HER2-positive and 
HER2-negative subpopulations coexist.
The landscape of pharmacological treatment of 
advanced HER2-positive breast cancer is rapidly evolving, 
and the potential collocation of a treatment with capecit-
abine + lapatinib will depend on new drugs becoming 
available. Anti-HER2 monoclonal antibodies and tyrosine 
kinase inhibitors differ in their mechanism of action and 
resistance [29, 30], and can complement each other when 
used in combination, concomitantly or in sequence. While 
other tyrosine kinase inhibitors, such as neratinib, are 
entering the clinical scenario, L could have a role beyond 
its combination with capecitabine or letrozole. Because 
capecitabine can be used in combination with trastuzumab, 
and could likely be used, in the future, with other drugs like 
neratinib, a possible use of PLD+ lapatinib is in patients 
pretreated with capecitabine. Patients intolerant to capecit-
abine, e.g., for dihydropyrimidine dehydrogenase (DPD) 
polymorphisms increasing its toxicity, could have the 
opportunity to receive lapatinib in combination with a non 
fluoropyrimidine agent.
Both L and PLD were proven to cross the blood–brain 
barrier, an important aspect in HER2-positive tumors 
which often lead to brain metastases [31, 32].
The small number of patients enrolled is the main limi-
tation of our study. Slow enrollment was due in part to 
competing studies on newer anti-HER2 drugs, and in part 
to difficulties in PLD supply, leading to a recommendation 
from EMA in September 2011 not to start new treatments 
with the drug (http://www.ema.europa.eu/docs/en_GB/doc-
ument_library/Medicine_QA/2011/09/WC500111745.pdf), 
and solved only in April 2013.
The RP2D emerging from our study is PLD 30 mg/m2 
every 3 weeks plus L 1500  mg/daily continuously. While 
PLD has been widely studied (mainly in a first-line setting) 
at a dose of 50 mg/m2/4 weeks, results from phase-II [33] 
and observational [34] studies showed that lower doses 
could be equally effective and better tolerated, with a dose 
intensity of 10  mg/m2/week suggested as the best choice 
[35]. For this reason, and because we were interested in 
long-term tolerability of the treatment, we decided not to 
proceed to dose level 3, and to consider dose level 2 as the 
RP2D.
A phase-II study with the same combination of PLD 
40  mg/m2/4 weeks plus L 1250  mg daily has been 
recently reported [36], showing good activity with 54% 
overall response rate in 24 patients, and good tolerability. 
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Although the intended dose intensity of PLD is the same 
as in our study (10 mg/m2/week), the dose of L is slightly 
lower. Nonetheless, while our study showed that PLD at 
10 mg/m2/week can be combined with L at 1500 mg/day 
in the first cycle, the actual median dose intensity of L 
during the whole treatment was <1250 mg/day (1220 mg/
day), even at dose level 2. Therefore, while selected 
patients may tolerate L at 1500  mg/day for long peri-
ods also in combination with PLD, a dose of 1250  mg/
day may be more suitable for most patients. Despite our 
RP2D for L showed acceptable initial tolerability, dose 
adjustments may be required to achieve the best therapeu-
tic index.
In conclusion, the limited toxicity of the combination 
and the hints of activity would support its further devel-
opment. Given the small and heterogeneous population, 
larger studies with different design would be needed to 
draw any conclusion concerning the potential additivity 
or synergy between the two agents.
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